EXAS vs. IRTC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EXAS and IRTC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | EXAS | IRTC |
|---|---|---|
| Company Name | Exact Sciences Corporation | iRhythm Technologies, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Equipment & Supplies |
| Market Capitalization | 12.87 billion USD | 5.22 billion USD |
| Exchange | NasdaqCM | NasdaqGS |
| Listing Date | February 1, 2001 | October 20, 2016 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of EXAS and IRTC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EXAS | IRTC |
|---|---|---|
| 5-Day Price Return | 0.68% | -3.11% |
| 13-Week Price Return | 47.00% | 6.38% |
| 26-Week Price Return | 24.89% | 22.21% |
| 52-Week Price Return | 32.13% | 96.05% |
| Month-to-Date Return | 3.62% | -8.80% |
| Year-to-Date Return | 19.29% | 89.44% |
| 10-Day Avg. Volume | 3.67M | 0.53M |
| 3-Month Avg. Volume | 2.86M | 0.44M |
| 3-Month Volatility | 29.23% | 31.51% |
| Beta | 1.43 | 1.13 |
Profitability
Return on Equity (TTM)
EXAS
-40.39%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
EXAS has a negative Return on Equity of -40.39%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
IRTC
-51.06%
Health Care Equipment & Supplies Industry
- Max
- 29.82%
- Q3
- 15.54%
- Median
- 9.69%
- Q1
- 5.19%
- Min
- -7.98%
IRTC has a negative Return on Equity of -51.06%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
EXAS
-32.01%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
EXAS has a negative Net Profit Margin of -32.01%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
IRTC
-7.32%
Health Care Equipment & Supplies Industry
- Max
- 24.65%
- Q3
- 14.10%
- Median
- 10.09%
- Q1
- 5.84%
- Min
- -6.13%
IRTC has a negative Net Profit Margin of -7.32%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
EXAS
-32.45%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
EXAS has a negative Operating Profit Margin of -32.45%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
IRTC
-9.08%
Health Care Equipment & Supplies Industry
- Max
- 31.34%
- Q3
- 18.36%
- Median
- 15.07%
- Q1
- 9.62%
- Min
- -0.13%
IRTC has a negative Operating Profit Margin of -9.08%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | EXAS | IRTC |
|---|---|---|
| Return on Equity (TTM) | -40.39% | -51.06% |
| Return on Assets (TTM) | -16.91% | -5.39% |
| Net Profit Margin (TTM) | -32.01% | -7.32% |
| Operating Profit Margin (TTM) | -32.45% | -9.08% |
| Gross Profit Margin (TTM) | 67.37% | 70.35% |
Financial Strength
Current Ratio (MRQ)
EXAS
2.72
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
EXAS’s Current Ratio of 2.72 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
IRTC
4.63
Health Care Equipment & Supplies Industry
- Max
- 4.97
- Q3
- 2.92
- Median
- 2.12
- Q1
- 1.54
- Min
- 0.86
IRTC’s Current Ratio of 4.63 is in the upper quartile for the Health Care Equipment & Supplies industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
EXAS
0.94
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
EXAS’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 0.94. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
IRTC
5.32
Health Care Equipment & Supplies Industry
- Max
- 1.62
- Q3
- 0.74
- Median
- 0.47
- Q1
- 0.15
- Min
- 0.00
With a Debt-to-Equity Ratio of 5.32, IRTC operates with exceptionally high leverage compared to the Health Care Equipment & Supplies industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
EXAS
-15.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
EXAS has a negative Interest Coverage Ratio of -15.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
IRTC
-32.60
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 24.86
- Median
- 9.84
- Q1
- 3.86
- Min
- -21.65
IRTC has a negative Interest Coverage Ratio of -32.60. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | EXAS | IRTC |
|---|---|---|
| Current Ratio (MRQ) | 2.72 | 4.63 |
| Quick Ratio (MRQ) | 2.24 | 4.37 |
| Debt-to-Equity Ratio (MRQ) | 0.94 | 5.32 |
| Interest Coverage Ratio (TTM) | -15.18 | -32.60 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
IRTC
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.36%
- Q3
- 1.87%
- Median
- 0.82%
- Q1
- 0.00%
- Min
- 0.00%
IRTC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
IRTC
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 67.77%
- Median
- 28.21%
- Q1
- 0.00%
- Min
- 0.00%
IRTC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | EXAS | IRTC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
EXAS
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for EXAS is currently unavailable.
IRTC
--
Health Care Equipment & Supplies Industry
- Max
- 67.59
- Q3
- 41.41
- Median
- 33.11
- Q1
- 22.82
- Min
- 8.68
P/E Ratio data for IRTC is currently unavailable.
Price-to-Sales Ratio (TTM)
EXAS
4.12
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
In the lower quartile for the Biotechnology industry, EXAS’s P/S Ratio of 4.12 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
IRTC
7.46
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.92
- Q1
- 1.97
- Min
- 0.61
IRTC’s P/S Ratio of 7.46 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
EXAS
4.14
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
EXAS’s P/B Ratio of 4.14 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
IRTC
45.33
Health Care Equipment & Supplies Industry
- Max
- 10.77
- Q3
- 6.04
- Median
- 3.32
- Q1
- 2.31
- Min
- 0.83
At 45.33, IRTC’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | EXAS | IRTC |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | -- |
| Price-to-Sales Ratio (TTM) | 4.12 | 7.46 |
| Price-to-Book Ratio (MRQ) | 4.14 | 45.33 |
| Price-to-Free Cash Flow Ratio (TTM) | 51.33 | 105.35 |